LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Pfizer

Chiusa

SettoreSettore sanitario

22.82 1.06

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

22.45

Massimo

22.82

Metriche Chiave

By Trading Economics

Entrata

2.6B

3B

Vendite

-4B

14B

P/E

Media del settore

16.732

56.602

EPS

0.92

Rendimento da dividendi

7.72

Margine di Profitto

21.633

Dipendenti

81,000

EBITDA

2B

4.5B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+26.88% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

7.72%

2.45%

Utili prossimi

29 lug 2025

Prossima data del Dividendo

13 giu 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-14B

131B

Apertura precedente

21.76

Chiusura precedente

22.82

Notizie sul Sentiment di mercato

By Acuity

43%

57%

150 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Pfizer Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2025, 18:41 UTC

I principali Market Mover

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 apr 2025, 11:24 UTC

Utili

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

15 mag 2025, 15:20 UTC

Notizie principali

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 18:45 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mag 2025, 17:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mag 2025, 09:02 UTC

Azioni calde

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 mag 2025, 17:01 UTC

Notizie principali

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mag 2025, 09:30 UTC

Notizie principali

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 mag 2025, 15:13 UTC

Discorsi di Mercato
Utili

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 mag 2025, 14:07 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 11:58 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 11:06 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 10:48 UTC

Utili

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 apr 2025, 19:47 UTC

Utili

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 apr 2025, 18:11 UTC

Utili

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 apr 2025, 15:22 UTC

Utili

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 apr 2025, 12:03 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 apr 2025, 11:46 UTC

Utili

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 apr 2025, 11:42 UTC

Utili

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 apr 2025, 11:12 UTC

Utili

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 apr 2025, 10:52 UTC

Utili

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 apr 2025, 10:51 UTC

Utili

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 apr 2025, 10:50 UTC

Utili

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 apr 2025, 10:47 UTC

Utili

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 apr 2025, 10:47 UTC

Utili

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 apr 2025, 10:46 UTC

Utili

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 apr 2025, 10:45 UTC

Utili

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29 apr 2025, 10:45 UTC

Utili

Pfizer 1Q EPS 52c >PFE

29 apr 2025, 10:45 UTC

Utili

Pfizer 1Q Adj EPS 92c >PFE

Confronto tra pari

Modifica del prezzo

Pfizer Previsione

Obiettivo di Prezzo

By TipRanks

26.88% in crescita

Previsioni per 12 mesi

Media 27.94 USD  26.88%

Alto 32 USD

Basso 24 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pfizer - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

5

Acquista

13

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

22.855 / 23.85Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

150 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.